Business Wire

Western Union Collaborates with Leading French Fintech Linxo to Launch Digital Money Transfers

Share

Western Union, a leader in cross-border, cross-currency money movement and payments, has collaborated with Linxo, a leading budget management and bank account aggregation application in France, to enable users to make local and cross-border payments through Western Union’s platform.

Linxo’s customers can now make and manage money transfers through Western Union’s platform, quickly, conveniently, and reliably, 24/7. Users can fund their transfers through their bank account or card, and have their funds paid out into billions of bank accounts and millions of mobile wallets in approximately 125 countries, or more than half a million retail locations in more than 200 countries and territories.

We are pleased to be joining forces with Linxo, offering the 3.5 million users of this innovative app access to the broadest digital global network coverage within the cross-border person-to-person payment sector,” said Massimiliano Alvisini, Head of Europe, CIS, and Africa Network at Western Union. “In France, and across the world, we partner with fintechs, banks and post offices, offering their customers flexibility and trust underpinned by technology, customer experience and compliance,” he said.

Established in 2010, Linxo is a pioneering account aggregation fintech, that optimizes bank account and transaction management for its users. The Linxo application is available in both free and premium versions on the Apple App Store and on Google Play.

By integrating the Western Union platform into our Linxo Marketplace, we are providing our users with a new and seamless customer experience thanks to enhanced functionalities for the management of their financial assets from a single space: consultation and management of accounts, sending or transferring money to their families and loved ones,” comments Bruno Van Haetsdaele, CEO and Co-Founder of Linxo Group. “Our ambition was to create a virtuous and open ecosystem. With the integration of the Western Union platform, this is now a reality. And we will continue to integrate new value-added services to provide our users with a quality service that exceeds their expectations within the Linxo application.”

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows, and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect businesses, financial institutions, governments, and consumers through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and over half a million-retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com

About Linxo

Linxo Group is a subsidiary of Crédit Agricole Payment Services, which {harnesses} Crédit Agricole Group’s expertise in marketing, innovation, processing and interbank representation. Since 2010, Linxo Group has been developing and marketing solutions for account aggregation, payment initiation and personal finance management.

The platform of its subsidiary Oxlin, a payment institution authorised by the ACPR [French Prudential Supervision and Resolution Authority], provides all the technology to access banking data and initiate transfers (services regulated by the Revised European Payment Services Directive no. 2, known as PSD2), with the customer's consent and in a totally secure manner.

The services it offers range from API (Application Program Interface) bricks to complete white-label mobile app solutions covering the needs of start-ups as well as banks and insurance companies. These solutions enable the development of new services and new sources of revenue from multiple use cases: budget management, pathways to credit grants, accounting, loyalty, etc.

Its mobile application Linxo, which is already installed and used by more than 3 million people in France, is an intelligent financial assistant, which allows everyone to have an overview of their finances and to simplify the management of their money.

The company has 85 employees, mainly in Aix-en-Provence and in the Crédit Agricole Villages in Paris and Sophia Antipolis.

WU-G

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts:
Nicholas Mandalas
Nicholas.Mandalas@wu.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 14:05:00 EEST | Press release

IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transform not only the country but the EU,” said Niccolo de Masi, Chairman and CEO of IonQ. “Through this landmark quantum collabora

Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 13:01:00 EEST | Press release

Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective cooling. The outcome is less pipe clutter, and less noise for mo

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will be presented, highlighting promising antitumor activity and a generally manageable safety and tolerability profile in patients with advanced solid tumors. “The results presented at ESMO 2025 strengthen the evidence base for TEVIMBRA in lung cancer, with consistent survival ben

SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 12:00:00 EEST | Press release

SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock

New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EUR neffy ® , Now Available in the UK20.10.2025 11:01:00 EEST | Press release

For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye